Justin G. Trogdon

Justin G. Trogdon

Auto-generated profile, based on publicly available information

Justin G. Trogdon

Affiliations Department of Health Policy and Management, Gillings School of Global Public Health, University of North Carolina at Chapel Hill, Chapel Hill, North Carolina, United States of America, Lineberger Comprehensive Cancer Center, University of North Carolina at Chapel Hill, Chapel Hill, North Carolina, United States of America

Research Focus & Metrics

Academic Career Length

17Years (2010-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
6 July 2021 in JNCI Cancer Spectrum
Verified
Journal Article
Open access
PDF file
AGAnagha Gogate
Anagha Gogate
SWStephanie B Wheeler
Stephanie B Wheeler
KRKatherine E Reeder-Hayes
Katherine E Reeder-Hayes
DEDonatus U Ekwueme
Donatus U Ekwueme
TFTemeika L Fairley
Temeika L Fairley
JTJustin G Trogdon
Justin G Trogdon
Background: This study projected the number of metastatic breast cancer (mBC) cases and costs (medical and productivity) attributable to mBC through 2030 among 3 age groups: younger (aged 18-44 years), midlife (aged 45-64 years), and older women (aged 65 years and older). Methods: We developed a stock/flow model in which women enter the mBC population at initial diagnosis (de novo stage IV) or through progression of an earlier-stage cancer. Women exit the mBC population through death. Input parameters by age and phase of treatment came from the US Census, Surveillance, Epidemiology, and End Results and peer-reviewed literature. Results: In 2030, we estimated there would be 246 194 prevalent cases of mBC, an increase of 54.8% from the 2015 estimate of 158 997. We estimated total costs (medical and productivity) of mBC across all age groups and phases of care were $63.4 billion (95% sensitivity range = $59.4-$67.4 billion) in 2015 and would increase to $152.4 billion (95% sensitivity range = $111.6-$220.4 billion) in 2030, an increase of 140%. Trends in estimated costs were higher for younger and midlife women than for older women. Conclusions: The cost of mBC could increase substantially in the coming decade, especially among younger and midlife women. Although accounting for trends in incidence, progression, and survival, our model did not attempt to forecast structural changes such as technological innovations in breast cancer treatment and health-care delivery reforms. These findings can motivate early detection activities, direct value-driven mBC treatment, and provide a useful baseline against which to measure the effect of prevention and treatment efforts.

9 September 2021 in Cancer Epidemiology, Biomarkers & Prevention
Verified
Journal Article
Open access
PDF file
JSJennifer C. Spencer
Jennifer C. Spencer
NBNoel T. Brewer
Noel T. Brewer
TCTamera Coyne-Beasley
Tamera Coyne-Beasley
JTJustin G. Trogdon
Justin G. Trogdon
MWMorris Weinberger
Morris Weinberger
SWStephanie B. Wheeler
Stephanie B. Wheeler
Background: Near elimination of cervical cancer in the United States is possible in coming decades, yet inequities will delay this achievement for some populations. We sought to explore the effects of human papillomavirus (HPV) vaccination on disparities in cervical cancer incidence between high- and low-poverty U.S. counties.Methods: We calibrated a dynamic simulation model of HPV infection to reflect average counties in the highest and lowest quartile of poverty (percent of population below federal poverty level), incorporating data on HPV prevalence, cervical cancer screening, and HPV vaccination. We projected cervical cancer incidence through 2070, estimated absolute and relative disparities in incident cervical cancer for high- versus low-poverty counties, and compared incidence with the near-elimination target (4 cases/100,000 women annually).Results: We estimated that, on average, low-poverty counties will achieve near-elimination targets 14 years earlier than high-poverty counties (2029 vs. 2043). Absolute disparities by county poverty will decrease, but relative differences are estimated to increase. We estimate 21,604 cumulative excess cervical cancer cases in high-poverty counties over the next 50 years. Increasing HPV vaccine coverage nationally to the Healthy People 2020 goal (80%) would reduce excess cancer cases, but not alter estimated time to reach the near-elimination threshold.Conclusions: High-poverty U.S. counties will likely be delayed in achieving near-elimination targets for cervical cancer and as a result will experience thousands of potentially preventable cancers.Impact: Alongside vaccination efforts, it is important to address the role of social determinants and health care access in driving persistent inequities by area poverty.

3 September 2015 in Preventing Chronic Disease
Verified
Journal Article
Open access
JTJustin G. Trogdon
Justin G. Trogdon
LMLouise B. Murphy
Louise B. Murphy
OKOlga A. Khavjou
Olga A. Khavjou
RLRui Li
Rui Li
CMChristopher M. Maylahn
Christopher M. Maylahn
DODiane Orenstein
Diane Orenstein
Many studies have estimated national chronic disease costs, but state-level estimates are limited. The Centers for Disease Control and Prevention developed the Chronic Disease Cost Calculator (CDCC), which estimates state-level costs for arthritis, asthma, cancer, congestive heart failure, coronary heart disease, hypertension, stroke, other heart diseases, depression, and diabetes. Using publicly available and restricted secondary data from multiple national data sets from 2004 through 2008, disease-attributable annual per-person medical and absenteeism costs were estimated. Total state medical and absenteeism costs were derived by multiplying per person costs from regressions by the number of people in the state treated for each disease. Medical costs were estimated for all payers and separately for Medicaid, Medicare, and private insurers. Projected medical costs for all payers (2010 through 2020) were calculated using medical costs and projected state population counts. Median state-specific medical costs ranged from $410 million (asthma) to $1.8 billion (diabetes); median absenteeism costs ranged from $5 million (congestive heart failure) to $217 million (arthritis). CDCC provides methodologically rigorous chronic disease cost estimates. These estimates highlight possible areas of cost savings achievable through targeted prevention efforts or research into new interventions and treatments.

1 February 2020 in The American Journal of Emergency Medicine
Verified
Journal Article
Closed access
ATAmir Alishahi Tabriz
Amir Alishahi Tabriz
JTJustin G. Trogdon
Justin G. Trogdon
BFBruce J. Fried
Bruce J. Fried

28 April 2020 in Breast Cancer Research and Treatment
Verified
Journal Article
Closed access
PDF file
JTJustin G. Trogdon
Justin G. Trogdon
CBChristopher D. Baggett
Christopher D. Baggett
AGAnagha Gogate
Anagha Gogate
KRKatherine E. Reeder-Hayes
Katherine E. Reeder-Hayes
JRJason Rotter
Jason Rotter
SWStephanie B. Wheeler
Stephanie B. Wheeler

10 July 2020 in Cancer
Verified
Journal Article
Closed access
PDF file
JTJustin G. Trogdon
Justin G. Trogdon
XLXuejun Liu
Xuejun Liu
KRKatherine E. Reeder‐Hayes
Katherine E. Reeder‐Hayes
JRJason Rotter
Jason Rotter
DEDonatus U. Ekwueme
Donatus U. Ekwueme
SWStephanie B. Wheeler
Stephanie B. Wheeler